4DMEDICAL Ltd Eyes US$20M Veterans Lung Imaging Pilot in Bipartisan Bill [VIDEO]
A bipartisan US bill authorising US$20 million for a VA 4D lung imaging pilot has put 4DMedical's FDA-cleared XV LVAS® squarely in the frame — here's what investors need to know about the AIR CARE for Vets Act and what happens next.
Key Takeaways
- A bipartisan US House bill — the AIR CARE for Vets Act (H.R.9666) — has been introduced to establish a VA pilot program using 4D functional lung imaging software, with US$20 million in authorised funding.
- 4DMedical's FDA-cleared XV LVAS® fits the bill's eligibility definition precisely, though the legislation does not name the Company, leaving the door open to any qualifying product.
- The bill was jointly introduced by two members of the House Committee on Veterans' Affairs — one Republican, one Democrat — and has been referred to that committee for consideration of further progress.
- Peer-reviewed multicentre research showed XV Technology® detected deployment-related constrictive bronchiolitis in Veterans even when standard spirometry was normal, providing a clinically differentiated argument for adoption in this patient population.
- Congressional interest in 4D functional lung imaging for Veterans dates to 2022, and 4DMedical already holds US reimbursement pathways, a growing clinical site base, and a SaaS delivery model that mirrors the licensing structure the VA bill would contemplate.
![Immuron Ltd Posts AUD$7.7M FY26 Sales After Four Quarters of Growth [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2F277adf25-75c7-41c7-9122-1c9b621267252Fimage_0.jpg)
![Algorae Pharmaceuticals Ltd Appoints Nasdaq Pharma Chair Troy Valentine [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fc2e5bc46-118e-4f4a-af83-4a9b296665f22Fimage_0.jpg)
![Immuron Ltd Engages Pullan Consulting for IMM-529 Partnering Strategy [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fce7cfc09-0087-4fd3-8a56-86ebd3a896c82Fimage_0.jpg)
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.